Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 1
1997 2
1998 1
2000 4
2001 3
2004 3
2005 3
2006 1
2007 4
2008 3
2009 1
2010 2
2013 2
2014 5
2015 1
2016 2
2017 1
2019 1
2020 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Muik A, Garralda E, Altintas I, Gieseke F, Geva R, Ben-Ami E, Maurice-Dror C, Calvo E, LoRusso PM, Alonso G, Rodriguez-Ruiz ME, Schoedel KB, Blum JM, Sänger B, Salcedo TW, Burm SM, Stanganello E, Verzijl D, Vascotto F, Sette A, Quinkhardt J, Plantinga TS, Toker A, van den Brink EN, Fereshteh M, Diken M, Satijn D, Kreiter S, Breij ECW, Bajaj G, Lagkadinou E, Sasser K, Türeci Ö, Forssmann U, Ahmadi T, Şahin U, Jure-Kunkel M, Melero I. Muik A, et al. Among authors: forssmann u. Cancer Discov. 2022 May 2;12(5):1248-1265. doi: 10.1158/2159-8290.CD-21-1345. Cancer Discov. 2022. PMID: 35176764 Free PMC article. Clinical Trial.
Conservative surgical treatment of diffuse peritonitis.
Seiler CA, Brügger L, Forssmann U, Baer HU, Büchler MW. Seiler CA, et al. Among authors: forssmann u. Surgery. 2000 Feb;127(2):178-84. doi: 10.1067/msy.2000.101583. Surgery. 2000. PMID: 10686983
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer.
Koopman LA, Terp MG, Zom GG, Janmaat ML, Jacobsen K, Gresnigt-van den Heuvel E, Brandhorst M, Forssmann U, de Bree F, Pencheva N, Lingnau A, Zipeto MA, Parren PW, Breij EC, Ditzel HJ. Koopman LA, et al. Among authors: forssmann u. JCI Insight. 2019 Nov 1;4(21):e128199. doi: 10.1172/jci.insight.128199. JCI Insight. 2019. PMID: 31600169 Free PMC article.
Pharmacokinetic and Pharmacodynamic Characteristics of Subcutaneously Applied PTH-1-37.
Forssmann WG, Tillmann HC, Hock D, Forssmann K, Bernasconi C, Forssmann U, Richter R, Hocher B, Pfützner A. Forssmann WG, et al. Among authors: forssmann u. Kidney Blood Press Res. 2016;41(5):507-518. doi: 10.1159/000443453. Epub 2016 Aug 4. Kidney Blood Press Res. 2016. PMID: 27487342 Free article. Clinical Trial.
A method for HLA-DQA typing by the PCR-SSP technique.
Forssmann U, Mytilineos J, Scherer S, Opelz G. Forssmann U, et al. Transpl Int. 1994;7 Suppl 1:S515-8. doi: 10.1111/j.1432-2277.1994.tb01432.x. Transpl Int. 1994. PMID: 11271295
Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers.
Gross S, Lennerz V, Gallerani E, Mach N, Böhm S, Hess D, von Boehmer L, Knuth A, Ochsenbein A, Gnad-Vogt U, Forssmann U, Woelfel T, Kaempgen E. Gross S, et al. Among authors: forssmann u. Cancer Immunol Res. 2016 Jan;4(1):18-25. doi: 10.1158/2326-6066.CIR-15-0105. Epub 2015 Nov 12. Cancer Immunol Res. 2016. PMID: 26563311 Clinical Trial.
Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism.
Overdijk MB, Strumane K, Beurskens FJ, Ortiz Buijsse A, Vermot-Desroches C, Vuillermoz BS, Kroes T, de Jong B, Hoevenaars N, Hibbert RG, Lingnau A, Forssmann U, Schuurman J, Parren PWHI, de Jong RN, Breij ECW. Overdijk MB, et al. Among authors: forssmann u. Mol Cancer Ther. 2020 Oct;19(10):2126-2138. doi: 10.1158/1535-7163.MCT-20-0044. Epub 2020 Aug 26. Mol Cancer Ther. 2020. PMID: 32847982
41 results